Elsevier

Neuropharmacology

Volume 51, Issue 5, October 2006, Pages 1013-1022
Neuropharmacology

Neuropeptide Y and corticotropin-releasing factor bi-directionally modulate inhibitory synaptic transmission in the bed nucleus of the stria terminalis

https://doi.org/10.1016/j.neuropharm.2006.06.011Get rights and content

Abstract

Neuropeptide Y (NPY) and corticotropin-releasing factor (CRF) have opposing effects on stress and anxiety. Both can modify synaptic activity through their binding to NPY receptors (YRs) and CRF receptors (CRFRs) respectively. The bed nucleus of the stria terminalis (BNST) is a brain region with enriched expression of both NPY and YRs and CRF and CRFRs. A component of the “extended amygdala”, the BNST is anatomically well-situated to integrate stress and reward-related processing in the CNS, regulating activation of the hypothalamic-pituitary-adrenal (HPA) axis and reward circuits. Using whole-cell recordings in a BNST slice preparation, we found that NPY and CRF inhibit and enhance GABAergic transmission, respectively. Pharmacological experiments suggest that NPY depresses GABAergic transmission through activation of the Y2 receptor (Y2R), while both pharmacological and genetic experiments suggest that CRF and urocortin enhance GABAergic transmission through activation of the CRF receptor 1 (CRFR1). Further, the data suggest that NPY acts to regulate GABA release, while CRF enhances postsynaptic responses to GABA. These results suggest potential anatomical and cellular substrates for the robust behavioral interactions between NPY and CRF.

Introduction

Anxiety disorders are serious medical conditions that have been estimated to impact approximately 20% of the population (Greenberg et al., 1999). While anxiety is a normal reaction to stress, repeated or severe stressors can produce pathological behaviors such as those seen in post-traumatic stress disorder (PTSD) and generalized anxiety disorder (Shekhar et al., 2005). An understanding of the neuronal and molecular targets associated with these conditions will likely promote more effective treatments. While classical neurotransmitters, such as gamma-aminobutyric acid (GABA) (Nemeroff, 2003) and glutamate (Javitt, 2004), have been implicated in these disorders, another class of signaling compounds, neuropeptides, are also thought to be involved in these conditions (Valdez and Koob, 2004). Neuropeptides are potent neuromodulators in the CNS whose actions are mediated via G-protein coupled receptors (Ludwig and Leng, 2006). In contrast to classical neurotransmitters, they are released in a frequency dependent fashion and often have a longer half-life of activity after release. These factors among others enable neuropeptides to produce long-lasting effects on cellular functions such as excitatory (Acuna-Goycolea et al., 2005) and inhibitory (Nie et al., 2004) synaptic transmission, neuronal excitability (Acuna-Goycolea et al., 2005) and gene transcription (Zhao et al., 2002). Thus, a long-lasting dysregulation of neuropeptides could have significant effects on the activity of neurons and consequentially, behavior.

A large body of literature implicates neuropeptide Y (NPY) as one of several neuropeptides involved in regulation of both anxiety and stress. Early pharmacological studies demonstrated that central infusion of NPY can reduce anxiety-like behaviors (Heilig et al., 1989). Conversely, mice with targeted deletions of NPY (Bannon et al., 2000) exhibit anxiety-like behaviors. Moreover, a recent study conducted in veterans exposed to combat suggested that NPY may play a role as a “stress protective” factor for individuals at risk for PTSD (Yehuda et al., 2006).

In contrast to NPY, the neuropeptide corticotrophin releasing factor (CRF) is thought to be primarily anxiogenic. Central administration of CRF causes an increase in anxiety-like behaviors, as well as activation of the stress response (Campbell et al., 2004). CRF knockout mice have significantly lower levels of corticosterone, both basally and following exposure to acute stress (Dunn and Swiergiel, 1999). Further, elevated CRF levels in the cerebrospinal fluid have been reported in persons diagnosed with PTSD (Bremner et al., 1997).

It has been proposed that dysregulation of NPY and CRF play opposing roles in regulation of anxiety disorders (Shekhar et al., 2005, Valdez and Koob, 2004). To date, however, a common site of opposing action has not been identified in situ. The bed nucleus of the stria terminalis (BNST), a brain region associated with anxiety, has enriched expression of both NPY (Walter et al., 1991) and YRs (Parker and Herzog, 1999), and CRF (Ju and Han, 1989) and CRFRs (Van Pett et al., 2000). The BNST receives a dense GABAergic and CRF input from the central nucleus of the amygdala (CeA) (Sakanaka et al., 1986), suggesting that CRF regulation of function in the BNST is critical for shaping BNST output. In keeping with this, pharmacological studies suggest that CRF signaling in the BNST is involved in anxiety (Lee and Davis, 1997, Sahuque et al., 2006) and stress-induced relapse to cocaine self-administration (Erb and Stewart, 1999). Moreover, a stimulus that promotes anxiogenic responses, the withdrawal of rodents from chronic ethanol exposure, produces rises in extracellular levels of CRF in the BNST (Olive et al., 2002), while acute heroin administration increases NPY immunoreactivity in the region (D'Este et al., 2006).

CRF (Nie et al., 2004) and NPY (Cowley et al., 1999, Pronchuk et al., 2002, Sun et al., 2001) have been shown to modulate GABAergic transmission, albeit in different brain regions. Interactions between these neuropeptides and GABAergic transmission have been proposed to underlie aspects of their regulation of animal behavior (Nie et al., 2004). Thus the BNST, in particular GABAergic transmission within the region, provides a potential anatomic and cellular substrate for interaction of CRF and NPY in regulating stress and anxiety. We have explored this possibility by investigating the actions of CRF and NPY on GABAergic transmission in the ventrolateral region of the BNST (vlBNST). This region projects to both the ventral tegmental area (VTA) (Dumont and Williams, 2004, Georges and Aston-Jones, 2002) and the paraventricular nucleus (PVN) of the hypothalamus (Cullinan et al., 1993), thus providing a point of access to both reward and stress pathways. Functionally the vlBNST is critical both for maintaining inhibitory tone on the PVN (Cullinan et al., 1993) and modulating stress induced relapse to drug seeking behavior (Erb et al., 2001). Given these findings, we reasoned that this would be a relevant region to investigate the actions of NPY and CRF, two neuropeptides known to regulate stress/anxiety responses.

Section snippets

Brain slice preparation

All procedures were performed according to Institutional Animal Care and Use Committee approved procedures. Male C57Bl/6J mice (6–8 weeks old, Jackson Laboratories) were decapitated under anesthesia (Isoflurane). The brains were quickly removed and placed in ice-cold sucrose artificial cerebrospinal fluid (ACSF): (in mM) 194 sucrose, 20 NaCl, 4.4 KCl, 2 CaCl2, 1 MgCl2, 1.2 NaH2PO4, 10.0 glucose, and 26.0 NaHCO3 saturated with 95% O2/5% CO2. Slices 300 μm in thickness were prepared using a Tissue

Results

We examined the effects of both NPY and CRF on inhibitory synaptic transmission in the vlBNST utilizing whole-cell voltage clamp of neurons from acutely prepared brain slices of adult mice. Local stimulation in the BNST produced an eIPSC that was driven by activation of GABAARs, as the selective GABAAR antagonist, SR95531 (GABAzine), completely blocked the response (Fig. 1A). We examined the current-voltage relationship for these eIPSCs (Fig. 1B) and found that the reversal potential was

Discussion

Abundant evidence suggests an antagonistic relationship of NPY and CRF signaling in the regulation of a variety of neuropsychiatric conditions. Here we provide a potential cellular substrate mediating this interaction by showing that NPY and CRF can bi-directionally modulate synaptic inhibition on a common pool of neurons in the BNST, a region critical for regulation of stress, anxiety and addiction. When presented in context of the connectivity of the BNST, these data thus provide at least one

Acknowledgements

This work was funded by INIA-STRESS (NIAAA) and NIDA. We thank Dr. Robert Kesterson for providing us with the CRFR2 knockout animals, and Dr. Robert Matthews for comments on a previous version of the manuscript.

References (47)

  • J.P. Redrobe et al.

    Neuropeptide Y (NPY) Y2 receptors mediate behaviour in two animal models of anxiety: evidence from Y2 receptor knockout mice

    Behav. Brain Res.

    (2003)
  • M. Sakanaka et al.

    Distribution and efferent projections of corticotropin-releasing factor-like immunoreactivity in the rat amygdaloid complex

    Brain Res.

    (1986)
  • A.P. Silva et al.

    Functional interaction between neuropeptide Y receptors and modulation of calcium channels in the rat hippocampus

    Neuropharmacology

    (2003)
  • G.R. Valdez et al.

    Allostasis and dysregulation of corticotropin-releasing factor and neuropeptide Y systems: implications for the development of alcoholism

    Pharmacol. Biochem. Behav.

    (2004)
  • D.L. Walker et al.

    Role of the bed nucleus of the stria terminalis versus the amygdala in fear, stress, and anxiety

    Eur. J. Pharmacol.

    (2003)
  • A. Walter et al.

    Differential distribution of immunohistochemical markers in the bed nucleus of the stria terminalis in the human brain

    J. Chem. Neuroanat.

    (1991)
  • R. Yehuda et al.

    Plasma neuropeptide Y concentrations in combat exposed veterans: relationship to trauma exposure, recovery from PTSD, and coping

    Biol. Psychiatry

    (2006)
  • H. Zhao et al.

    Effect of orphanin FQ on interleukin-1beta mRNA transcripts in the rat CNS

    Neuroscience

    (2002)
  • C. Acuna-Goycolea et al.

    Mechanisms of neuropeptide Y, peptide YY, and pancreatic polypeptide inhibition of identified green fluorescent protein-expressing GABA neurons in the hypothalamic neuroendocrine arcuate nucleus

    J. Neurosci.

    (2005)
  • J.D. Bremner et al.

    Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder

    Am. J. Psychiatry

    (1997)
  • S.C. Coste et al.

    Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2

    Nat. Genet.

    (2000)
  • W.E. Cullinan et al.

    Ventral subicular interaction with the hypothalamic paraventricular nucleus: evidence for a relay in the bed nucleus of the stria terminalis

    J. Comp. Neurol.

    (1993)
  • E.C. Dumont et al.

    Noradrenaline triggers GABAA inhibition of bed nucleus of the stria terminalis neurons projecting to the ventral tegmental area

    J. Neurosci.

    (2004)
  • Cited by (146)

    • Neuropeptide Y modulates excitatory synaptic transmission and promotes social behavior in the mouse nucleus accumbens

      2022, Neuropharmacology
      Citation Excerpt :

      In mice and rats, NPY modulates neuronal activity by activating potassium channels and/or inhibiting calcium channels both pre- and postsynaptically (Fu et al., 2004; Van Den Pol et al., 2004; Sun et al., 2001a; Sun et al., 2001b; McQuiston et al., 1996; Acuna-Goycolea et al., 2005; Acuna-Goycolea and Van Den Pol, 2005; Roseberry et al., 2004; West and Roseberry, 2017). Additionally, NPY has been found to act presynaptically to inhibit vesicular release of both glutamate and GABA (Fu et al., 2004; Van Den Pol et al., 2004; Sun et al., 2001b; Acuna-Goycolea et al., 2005; Acuna-Goycolea and Van Den Pol, 2005; West and Roseberry, 2017; Kash and Winder, 2006; Chen and Van Den Pol, 1996; Cowley et al., 1999; Molosh et al., 2013; Gilpin et al., 2011). However, it is currently unclear whether NPY engages these mechanisms in the NAc to regulate synaptic transmission.

    • Regulation of alcohol drinking by ventral striatum and extended amygdala circuitry

      2022, Neuropharmacology
      Citation Excerpt :

      Bath application of NPY to an ex vivo slice preparation of the BNST increases presynaptic GABA release via activation of the complementary receptor Y2R. Contrarily, application of CRF decreases GABAergic transmission through a CRFR1 mediated change to the postsynaptic response to GABA (Kash and Winder, 2006). In adult, male B6 mice, agonism of Y1R (with LeuPro-NPY) in the BNST decreases ethanol intake in the first 2 h, but not the second 2 h of a 4-h DID binge-drinking session (Pleil et al., 2015b).

    View all citing articles on Scopus
    View full text